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Summary
Background and purpose: The long-term safety and efﬁcacy of primary stenting using drug-
eluting stents (DES) in patients with ST-segment elevation myocardial infarction (STEMI) are notDrug-eluting stent;
Stent thrombosis
fully understood in Japan. Therefore, we retrospectively examined the midterm clinical and
angiographic outcomes in STEMI patients after primary stenting using sirolimus-eluting stents
(SES) in a clinical setting through a historical comparison with those of bare-metal stents (BMS).
Methods and results: The study design was a retrospective, nonrandomized, and single-center
study. The clinical outcomes for 568 consecutive patients who presented within 12 h of their
ﬁrst STEMI and who were treated with BMS (n = 198; 184 STEMIs from June 2003 to August 2004
and 14 STEMIs from September 2004 to May 2007) or SES (n = 370; from August 2004 to May
∗ Corresponding author. Tel.: +81 485 36 9900x2250; fax: +81 485 36 9920.
E-mail address: ishikawa.tetsuya@pref.saitama.lg.jp (T. Ishikawa).
914-5087/$ — see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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2007) at our medical center in Japan were retrospectively investigated in February 2010. The
incidence of post-discharge events (comprising cardiac death and nonfatal recurrent MI) after
SES placement (3.9%) was not signiﬁcantly different from that after BMS placement (6.7%). SES
was not related to the risk of post-discharge events (mean follow-up for SES, 1327± 415 days;
BMS, 1818± 681 days) (hazard ratio of 0.369 at 95% CI, 0.119—1.147, p = 0.085). The incidence of
deﬁnite stent thromboses after SES placement (0.54%) was not signiﬁcantly higher than that after
BMS placement (0%). The incidence of binary in-stent restenosis (% diameter stenosis of more
than 50% at secondary angiography) after SES placement (8.3%) was signiﬁcantly lower than that
after BMS placement (25.7%; p < 0.001).
Conclusions: From the present historical comparison of SES and BMS, we conclude that pri-
mary stenting using SES in a clinical setting has favorable clinical and angiographic outcomes in
ardi
M
P
T
t
[
a
[
g
n
p
N
t
S
n
t
w
m
d
n
r
p
c
s
e
r
T
p
g
2
c
m
a
v
i
c
a
m
t
approximately 6—12 months after primary stenting for the
BMS group and approximately at 10—18 months for the SESJapanese STEMI patients.
© 2011 Japanese College of C
Introduction
Several randomized prospective studies have compared the
safety and efﬁcacy of primary stenting using sirolimus-
eluting stents (SES) (Cypher; Cordis Corp., Miami, FL, USA)
and bare-metal stents (BMS) in patients with ST-segment
elevation myocardial infarction (STEMI) [1—3]. However,
because of the exclusion criteria in these studies [1—3],
the safety and efﬁcacy of SES required to support the rou-
tine clinical use of primary stenting in all STEMI patients,
including high-risk STEMI patients, are not completely
understood [4]. Therefore, the long-term durability of pri-
mary stenting using SES in clinical practice remains to be
examined.
In Japan, only a few studies have investigated the
short-term safety after primary stenting using SES in STEMI
patients [5,6]. The guideline set forth by the Japanese Cir-
culation Society [7] states that the long-term safety and
efﬁcacy of primary stenting using SES in a relatively large
patient population with STEMI have not been fully investi-
gated in Japan. SES was not used in patients with STEMI
because of the major risk of stent thrombosis (ST) associ-
ated with primary stenting using drug-eluting stents (DES)
[8], i.e. the incidence of ST, was not fully understood.
However, the percentage of ST in Japan is signiﬁcantly
lower than that in Western countries [9—11]. Therefore,
the evaluation of long-term safety after primary stenting
using SES in Japanese STEMI patients is important; further-
more, the incidence of ST after SES placement in Japanese
patients should be compared with that from western coun-
tries [1—4].
In this study, to examine the midterm safety and efﬁ-
cacy of primary stenting using SES in a routine clinical
setting in Japan, we retrospectively investigated the clin-
ical and angiographic outcomes after primary stenting using
SES in STEMI patients. The 568 consecutive patients pre-
senting within 12 h of their ﬁrst STEMI were retrospectively
compared for the incidences of (A) post-discharge events
composite of death without deﬁnite non-cardiac death and
nonfatal recurrent MI (re-MI); (B) angiographic binary in-
stent restenosis [% diameter stenosis (DS) of more than 50%
at the follow-up angiogram (fu CAG)]; and (C) the inci-
dences of all (early, late, and very late) deﬁnite ST, as
deﬁned by the Academic Research Consortium (ARC) [12],
after SES placement and after BMS placement under ticlo-
pidine.
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ethods
opulation
he rationale of almost unrestricted use of DES, including
heir use in STEMI patients, has been previously reported
5,11]. From June 2003 to August 2004 (before SES was
pproved in Japan), 184 patients, presenting within 12 h
13] of their ﬁrst STEMI without prior coronary artery bypass
rafts (CABG), were treated using BMS in the native coro-
ary arteries. From August 2004 to May 2007 [before the
aclitaxel-eluting stent (TAXUS Express; Boston Scientiﬁc,
atick, MA, USA) was approved in Japan], 14 patients were
reated using BMS and 370 patients were treated using
ES. The placement of SES or BMS after SES approval was
ot prospectively randomized. However, 14 patients were
reated using BMS for the following reasons: 3 patients
ith known malignancies and 2 patients with severe ane-
ia needed further investigations; 2 patients received BMS
ue to their preoperative states; in 2 patients, SES could
ot be delivered to the culprit lesion; 2 patients, a large
eference in the ectatic right coronary artery (RCA); 2
atients presented with an unknown clinical course (psy-
hologically instability and unconsciousness); and 1 patient
howed low compliance with drug continuation. Thus, we
nrolled 568 consecutive patients who had their ﬁrst occur-
ence of STEMI [BMS group (n = 198) and SES group (n = 370)].
he ratio of SES use was 96.4% in all primary stenting
erformed after SES approval. We retrospectively investi-
ated the clinical outcomes in the 568 patients in February
010. The incidences of in-hospital mortality (comprising
ardiac death and nonfatal recurrent MI) after SES place-
ent (n = 9, 2.4%) were not signiﬁcantly different from those
fter BMS placement (n = 4, 2.0%) (mean follow-up inter-
al for SES 13.0± 20.8 days; BMS 13.4± 10.4 days). Thus,
n the present study, the clinical and angiographic out-
omes in patients with SES placement who were discharged
live (n = 361) were compared with those with BMS place-
ent (n = 194). Angiographic outcomes at the fu CAG up
o February 2010 were included. The fu CAG was plannedroup. The percentage patient follow-up for the fu CAG in
he BMS group was 78.4% (152 patients of 194 patients),
nd in the SES group was 73.1% (264 of 361, no signiﬁcant
hange). After primary stenting, all patients were encour-
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aged to undergo optimal medical therapy according to the
guidelines for the management and secondary prevention of
MI, as outlined by the Japanese Circulation Society [7,14].
Oral beta-blockers as well as angiotensin-converting enzyme
inhibitors or angiotensin receptor-blockers were adminis-
tered as soon as possible by checking for a contraindication
(Table 1). A lipid-lowering therapy using HMG-CoA reduc-
Table 1 Post-discharge baseline characteristics of patients
receiving primary stenting with SES or BMS.
SES BMS
n = 361 n = 194
Age (years) 67.0± 11.6 65.5± 12.4
Male gender (%) 71.7 78.9
Diabetes (%) 40.7 38.1
Smoking (%) 56.2 58.8
Elapsed time (h) 3.73± 2.67 4.04± 2.53
Killip classiﬁcation 1.29± 0.68 1.22± 0.63
Killip 3—4 (%) 6.1 7.2
Cardiac dysfunction (%) 20.5 7.7***
First TIMI-grade 2—3 ﬂow
(%)
34.1 32.5
Rentrop-grade 2—3 (%) 12.2 13.9
Number of diseased
vessels
1.65± 0.73 1.57± 0.66
LAD/RCA/LMT 47.6/35.5/1.1 43.3/44.3*/0
Calciﬁcation (%) 3.9 4.6
Bifurcation (%) 29.4 8.2***
Thrombus (%) 14.7 22.7*
Number of stents 1.36± 0.56 1.23± 0.47**
Diameter of stent (mm) 3.29± 0.46 3.44± 0.61**
Length of stent (mm) 32.7± 15.8 25.0± 11.2***
Maximum pressure (atm) 19.6± 3.2 14.6± 2.7***
IVUS use (atm) 93.9 37.6***
Distal protection (%) 80.9 65.5***
Thrombectomy (%) 89.2 75.3***
Final TIMI-grade 2—3 ﬂow
(%)
98.1 97.9
Peak CK-MB (IU/dl) 372± 269 312± 249**
Medication at discharge
-Blocker (%) 69.3 68.9
ACE-I/ARB (%) 90.9 90.7
Statin (%) 69.3 68.0
Total endpoint (n, %) 14, 3.9 13, 6.7
Death (n, %) 12, 3.3 13, 6.7
Non-fatal re-MI (n, %) 2, 0.6 0
Post-discharge
observational duration
(days)
1327± 415 1818± 681***
Thirty-three baseline variables related to patients, clinical con-
dition, lesions, and procedure and endpoint are shown. The
deﬁnitions of the variables are described in the text.
* The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.05.
** The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.01.
*** The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.001.
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ant (statin) was also administered by checking the level of
erum low-density lipoprotein (Table 1). These drugs were
ontinuously administered after discharge.
rocedures for primary stenting and antiplatelet
herapy
he choice of the device used to restore a good coronary
ow was subject to the doctor’s discretion (nonrandomized
tudy). Stents were implanted by visual angiographic esti-
ation to cover the entire baseline lesion, and after SES
pproval, were implanted largely under the guidance of
ntravascular ultrasonography (IVUS-guide) (Table 1). When
urther stent dilation was needed, high-pressure balloon-
ng using a non-compliant balloon [15,16] was typically
arried out (Tables 1 and 3). Because the culprit lesions
n STEMI may develop through a slow- or no-reﬂow phe-
omenon, a distal protection method using the PercuSurge
uardWire® (Medtronic, Santa Rosa, CA, USA) device [17]
as preferred.
Periprocedural antiplatelet therapy was conducted, as
reviously reported [5,9,11]. At the emergency care unit,
efore performing primary percutaneous coronary interven-
ion (PCI), aspirin (162—200mg) and ticlopidine (200mg)
ere immediately given orally. After the procedure, ticlopi-
ine (200mg/day) was prescribed for at least 2 weeks for the
MS group and 12 weeks for the SES group. Although these
rescriptions were not prospectively randomized, ticlopi-
ine was prescribed for about 1 year in accordance with the
ecommended guidelines [18]. Cilostazol (200—300mg/day)
r clopidogrel (75mg/day) was administered at the doc-
or’s discretion if ticlopidine administration showed adverse
ffects.
ollow-up angiography and quantitative coronary
rtery angiography
he details of the duration for which fu CAG was performed
re given under ‘‘Methods.’’ The quantitative coronary
rtery angiography (QCA) parameters were measured using
he TCS cardiovascular network system, as described pre-
iously [19]; their values were obtained at 3 points: before
CI (preprocedural), immediately after successful PCI (post-
rocedural), and at the chronic phase (follow-up) (CAAS II
ystem, Pie Medical, Maastricht, The Netherlands). Minimal
umen diameter (MLD), %DS (described above), reference
iameter (RD), and lesion length were measured. In addi-
ion, acute gain (postprocedural MLD minus preprocedural
LD) and late luminal loss (postprocedural MLD minus MLD
t chronic phase) were calculated. Binary in-stent restenosis
binary restenosis) was deﬁned as %DS of <50% at the chronic
hase. Mehran et al. [20] reported that in-stent restenosis
ISR) was divided into focal (lesion length at chronic phase
10mm) (type 1) and diffuse (<10mm) (types 2, 3, 4) types.
he ratio of type 1 (focal type) ISR in the SES group was
ompared with that in the BMS group. Target lesion revascu-
arization (TLR) observed on the fu CAG was deﬁned as any
elective or emergency) repeated PCI or CABG performed,
ncluding ISR, at the 5-mm proximal and distal stent margins
20]. The need for TLR was decided primarily on the basis
f visual angiographic outcome [21], although the patient’s
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1Primary stenting using SES for STEMI in Japan
symptoms and the outcomes indicated by stress electrocar-
diograms, cardiac ultrasonography, and radionuclide images
were also considered.
Endpoints
The safety endpoints of the clinical outcomes were (A)
post-discharge events composite of death without deﬁnite
non-cardiac death and nonfatal re-MI. The efﬁcacy endpoint
of the angiographic outcome was (B) the incidence of binary
restenosis (deﬁned above). An additional outcome of inter-
est was (C) deﬁnite (early, late, and very late) ST, as deﬁned
by the ARC [12].
Estimated variables
The deﬁnitions of the variables used as baseline character-
istics, namely, patient, clinical, lesion, and procedure at
discharge, were as follows: age (age at primary stenting);
male gender; diabetes (patients with diabetes mellitus);
smoking (smoker at the time of primary stenting); elapsed
time (interval after onset until arrival); Killip classiﬁcation
[22]; Killip 3—4 (Killip classiﬁcation 3 or 4); cardiac dys-
function (ejection fraction of left ventricle less than 40
as evaluated by ultrasonography or left ventriculogram);
ﬁrst TIMI-grade 2—3 ﬂow (TIMI-grade 2 or 3 ﬂow at the
ﬁrst angiogram); Rentrop grade 2—3 (Rentrop grade 2 or
3 for collateral ﬂow); number of diseased vessels (number
of diseased vessels of the native coronary artery); loca-
tion of the culprit lesion in the left anterior descending
(LAD) artery, RCA, or left main trunk (LMT); calciﬁcation
(calciﬁed lesions, estimated using an angiogram and IVUS);
bifurcation (bifurcative lesions requiring any treatment of
the side branch); thrombus (thrombus-containing lesion;
the previous 4 variables have been deﬁned according to
the American College of Cardiology/American Heart Asso-
ciation classiﬁcation of lesions); number of stents (number
of implanted stents per lesion); diameter of stent (max-
imum diameter of the balloon used to dilate the stent);
length of stent (length of the stented segment, calculated
by adding the length of each stent, regardless of overlap);
maximum pressure (maximum pressure at the maximum
inﬂation diameter of the balloon); IVUS use (availability of
IVUS during PCI); distal protection (lesions treated with the
PercuSurge GuardWire device); thrombectomy (performing
thrombectomy using any thrombosuction catheter); ﬁnal
TIMI-grade 2—3 ﬂow (postprocedural TIMI-grade 2 or 3 ﬂow);
peak CK-MB (peak serum level of myocardial creatine kinase
isoenzyme measured every 3 h); and post-discharge obser-
vational duration (duration in days until censored after
discharge).
Statistics
Baseline characteristic variables are expressed as a
mean value± standard deviation (SD). Comparisons of
variables between the BMS and SES groups were con-
ducted using unpaired t-tests for continuous values and
2 tests for categorical values. Predictors of binary
restenosis were analyzed using logistic regression anal-
C
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p
p47
sis by including 27 related variables, as shown in
ables 3 and 4. Cumulative post-discharge endpoint-
ree and binary restenosis-free ratios were expressed
sing Kaplan—Meier curves. The Cox proportional hazard
odel was used to analyze the predictors of post-
ischarge events by including 22 related variables. A
ifference was considered signiﬁcant when the p-value
as less than 0.05. Stata for Windows version 8 (Stata-
orp, College Station, TX, USA) was used for statistical
nalysis.
esults
ost-discharge baseline characteristics
able 1 shows the post-discharge baseline characteristics
f patients receiving primary stenting with SES (n = 361)
nd BMS (n = 194). Thirteen variables in the SES group
ere signiﬁcantly different from those in the BMS group.
mong patient and clinical characteristics, the percentage
f cardiac dysfunction (20.5%) and the mean peak level
f CK-MB (372± 269 IU/dl) in the SES group were signiﬁ-
antly different from those in the BMS group (p < 0.001 and
< 0.01, respectively). Among the lesion characteristics,
he percentages of bifurcation lesions (29.4%), thrombus
esions (14.7%), and RCA lesions (35.5%) in the SES group
ere signiﬁcantly different from those in the BMS group
p < 0.001, p < 0.05, and p < 0.05, respectively). Among the
rocedural characteristics, IVUS use (93.9%), distal protec-
ion (80.9%), thrombectomy (89.2%), mean number of stents
1.36± 0.56), diameter of stents (3.29± 0.46), length of
tents (32.7± 15.8), and maximum pressure (19.6± 3.2) in
he SES group were signiﬁcantly different from those of the
MS group (p < 0.001, p < 0.001, p < 0.001, p < 0.01, p < 0.01,
< 0.001, and p < 0.001, respectively). The ratios of three
ypes of medicines for the secondary prevention at dis-
harge were not signiﬁcantly different in both groups. The
ean post-discharge observational duration in the SES group
1327± 415 days) was signiﬁcantly shorter than that in the
MS group (1818± 681 days, p < 0.001). The percentages of
ndpoints were not signiﬁcantly different between the 2
roups.
linical endpoint after discharge
he cumulative post-discharge endpoint-free ratio for the
ES group was not signiﬁcantly different from that for
he BMS group (p = 0.44, by the log-rank test) (Fig. 1),
lthough the cumulative post-discharge endpoint-free ratio
or the SES group was approximately 500 days less than
hat for the BMS group. Using the Cox proportional haz-
rd model, age [hazard ratio (HR) of 1.090, 95% CI,
.031—1.153, p < 0.01], Killip classiﬁcation (HR of 1.833, 95%
I, 1.124—2.990, p < 0.05), and calciﬁcation (HR of 3.794,
5% CI, 1.090—13.20, p < 0.05) were the signiﬁcant predic-
ors of post-discharge endpoints. SES was not related to the
ost-discharge endpoint (HR of 0.369, 95% CI, 0.119—1.147,
= 0.085) (Table 2).
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Table 2 Predictors of post-discharge endpoint.
Hazard ratio 95% CI p-Value
Lower limb Upper limb
Age 1.090 1.031 1.153 <0.01
Killip classiﬁcation 1.833 1.124 2.990 <0.05
Calciﬁcation 3.794 1.090 13.200 <0.05
Diabetes 2.453 0.931 6.464 0.070
...
...
SES 0.369 0.119 1.147 0.085
...
...
Predictors of post-discharge endpoint analyzed by the Cox proportional hazard model are shown. The deﬁnitions of the variables are
described in the text. The ﬁrst 3 variables were signiﬁcant predictors, but the others including SES were not related to the post-discharge
endpoint.
Angiographic outcomes
Table 3 shows the baseline characteristics of patients after
performing fu CAG. As shown in Table 1, 13 variables were
signiﬁcantly different between the SES (n = 264) and BMS
(n = 152) groups.
Table 4 shows the results from the serial QCA after
performing fu CAG. Eight variables were signiﬁcantly dif-
ferent in both groups, excluding pre and postprocedural
RD. Although the mean value of acute gain in the SES
group was not signiﬁcantly different from that in the
BMS group, that of late luminal loss in the SES group
(0.201± 0.658mm) was signiﬁcantly lower than that in the
BMS group (0.818± 0.705mm) (p < 0.001). The incidences of
binary restenosis (8.2%) and TLR (9.4%) in the SES group
were signiﬁcantly lower than those in the BMS group (24.7%
and 23.3%, p < 0.001 and p < 0.001, respectively). The inci-
dence of mild in-stent stenosis (%DS of more than 45% at the
. 7
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0 360 720 1080 1440 1800 2160 2520
Logrank
p = 0.44
BMS
SES
Post-discharge observational Interval (days)
Cumulative Post-discharge 
Endpoint-free ratios
Figure 1 Cumulative post-discharge endpoint-free ratios for
the bare-metal stents (BMS) and sirolimus-eluting stents (SES)
groups. The vertical axis expresses the cumulative post-
discharge endpoint-free ratio (%) and the horizontal axis
expresses the interval after discharge (days).
chronic phase) in the SES group (9.8%) was also signiﬁcantly
lower than that in the BMS group (32.2%, p < 0.001). The inci-
dence of type-1 (focal) ISR among all the binary restenoses
in the SES group (61.9%) was signiﬁcantly higher than that
in the BMS group (36.1%, p < 0.001). The mean observa-
tion interval for follow-up secondary angiograms taken after
primary stenting in the SES group (455± 269 days) was signif-
icantly longer than that for the BMS group (308± 394 days,
p < 0.001).
Fig. 2 shows that the cumulative binary restenosis-free
ratio for the SES group was signiﬁcantly higher than that for
the BMS group (p < 0.01, by the log-rank test).
Table 5 shows the predictors of binary restenosis using
logistic regression analysis. By a multivariate analysis, SES
[odds ratio (OR) of 0.231, 95% CI 0.129—0.413, p < 0.001]
and diameter of stent (OR of 0.475, 95% CI 0.266—0.851,
p < 0.05) were the predictors of binary restenosis in 416
.3
.4
.5
.6
.7
.8
.9
1
0 360 720 1080 1440 1800 2160
BMS
SES
Angiographic follow-up duration (days)
Log rank
p < 0.01
Cumulative Binary Restenosis-
free ratios after primary stenting
Figure 2 Cumulative binary restenosis-free ratios for the
bare-metal stents (BMS) and sirolimus-eluting stents (SES)
groups. The vertical axis expresses the cumulative binary
restenosis-free ratio (%) and the horizontal axis expresses
the interval after primary stenting until secondary angiogram
(days).
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Table 3 Baseline characteristics of patients after follow-
up secondary angiography.
SES BMS
n = 264 n = 152
Age (years) 64.2± 10.4 63.9± 10.7
Male gender (%) 75.4 80.9
Diabetes (%) 41.3 40.8
Smoking (%) 59.1 61.8
Elapsed time (h) 3.60± 2.64 4.01± 2.60
Killip classiﬁcation 1.22± 0.59 1.12± 0.46
Killip 3—4 (%) 4.2 3.3
Cardiac dysfunction
(%)
19.3 7.2***
First TIMI-grade 2—3
ﬂow (%)
29.9 29.6
Rentrop-grade 2—3
(%)
15.1 12.5
Number of diseased
vessels
1.59± 0.68 1.49± 0.61
LAD/RCA/LMT 49.6/33.0/0.8 41.4/46.1**/0
Calciﬁcation (%) 2.3 4.1
Bifurcation (%) 29.2 6.6***
Thrombus (%) 12.5 21.7*
Number of stents 1.38± 0.59 1.25± 0.49*
Diameter of stent
(mm)
3.28± 0.45 3.45± 0.59*
Length of stent (mm) 33.5± 16.3 25.2± 11.4***
Maximum pressure
(atm)
19.5± 3.1 14.6± 2.8***
IVUS use (%) 93.2 38.8***
Distal protection (%) 82.2 67.1***
Thrombectomy (%) 90.2 75.0***
Final TIMI-grade 2—3
ﬂow (%)
97.3 98.0
Peak CK-MB (IU/dl) 377± 269 318± 253*
Twenty-six baseline variables related to patients, clinical con-
dition, lesions, and procedure are shown. The deﬁnitions of the
variables are described in the text.
* The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.05.
** The signiﬁcance of the differences between the BMS and SES
Table 4 Serial quantitative coronary angiography ﬁndings
after follow-up secondary angiography.
SES BMS
n = 264 n = 152
Pre-procedural
MLD (mm) 0.296± 0.428 0.521± 0.676***
%DS 88.8± 15.7 82.9± 22.1**
RD (mm) 2.85± 0.535 2.88± 0.623
Lesion length (mm) 19.5± 9.53 15.3± 8.99***
Post-procedural
MLD (mm) 2.52± 0.441 2.65± 0.540**
%DS 14.7± 9.25 11.3± 12.8*
RD (mm) 2.97± 0.500 3.03± 0.633
Follow-up
MLD (mm) 2.32± 0.712 1.83± 0.813***
%DS 25.0± 18.7 36.7± 23.9***
RD (mm) 3.10± 0.564 2.86± 0.665***
Lesion length (mm) 4.83± 3.92 13.3± 9.39***
Acute gain (mm) 2.22± 0.588 2.13± 0.775
Late luminal loss (mm) 0.201± 0.658 0.818± 0.705***
Binary restenosis (%) 8.2 24.7***
Follow-up %DS≥ 45 (%) 9.8 32.2***
Type-1 ISR/total ISR (%) 61.9 36.1***
TLR (%) 9.4 23.3***
Angiographic follow-up
duration (days)
455± 269 308± 394***
Seventeen variables related to angiographic outcomes are
shown. The deﬁnitions of the variables are described in the text:
angiographic followed-up duration (duration until performing
latest followed-up angiogram after primary stenting).
* The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.05.
** The signiﬁcance of the differences between the BMS and SES
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bgroups is shown as p < 0.01.
*** The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.001.
STEMI patients after performing primary stenting with BMS
or SES. The length of stent was a signiﬁcant predic-
tor of binary restenosis, as determined by a univariate
analysis.
Incidence of deﬁnite stent thrombosis after
primary stenting
The incidence of total deﬁnite ST events in the SES
group (0.54%) (2 cases in 370 STEMIs) was not signif-
icantly different from that in the BMS group (0%). No
deﬁnite ST was observed in the BMS group after stent
placement in 198 patients. In the SES group, no deﬁnite
early and late ST was observed; however, 2 cases of def-
inite, very late ST were implicated in cardiac death and
a
>
i
I
pgroups is shown as p < 0.01.
*** The signiﬁcance of the differences between the BMS and SES
groups is shown as p < 0.001.
onfatal re-MI during the post-discharge observational inter-
al.
iscussion
his study mainly indicated a favorable midterm (a mean
ollow-up period of more than 1300 days) post-discharge
linical and angiographic outcomes of primary stenting using
ES in a routine clinical setting in Japanese STEMI patients
ith very low incidence of deﬁnite ST under aspirin plus
iclopidine therapy (Tables 2, 4 and 5; Figs. 1 and 2). The
resent study included the high-risk patients with com-
lex lesion-related cardiac events, ST events, and binary
estenosis, such as those with Killip 3—4 classiﬁcations [22],
ifurcation [23], calciﬁcation [24], thrombus lesions [25],
nd LMT lesions [22]; higher mean peak values of CK-MB
300 (IU/dl) [26], and longer stents [27] compared to those
n previous prospective randomized studies [1—3] (Table 1).
n addition, no use of glycoprotein IIb/IIIa inhibitors [28], a
roportion of diabetic patients as high as 40% [29], and a
50 T. Ishikawa et al.
Table 5 Predictors of in-stent binary restenosis.
Univariate analysis Multivariate analysis
Odds ratio 95% CI p-Value Odds ratio 95% CI p-Value
Lower limb Upper limb Lower limb Upper limb
SES 0.095 0.037 0.243 <0.001 0.231 0.129 0.413 <0.001
Diameter of stent 0.313 0.117 0.838 <0.05 0.475 0.266 0.851 <0.05
Length of stent 3.395 0.838 13.800 0.087
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iPredictors of in-stent binary restenosis (BR) analyzed by logistic
described in the text.
elatively high percentage of cardiac dysfunction [30] were
ome of the other characteristics of the cohort.
The long-term safety of SES use for STEMI patients has
een an unresolved issue in the DES era [4] and also in
apan [7]. Particularly, stent thromboses [early, late, and
ery late STs (VLST)] implicated in the devastating outcomes
ave been the major concern for DES use for STEMI [4],
ecause STEMI was a powerful predictor of ST [8,10]. In
he present cohort, the composite incident ratio of cardiac
eath and re-MI (6.3%) with mean follow-up periods (approx-
mately 3.5 years) was acceptable compared to the previous
eports from western countries after primary stenting using
ES for more than 150 STEMI patients [1—3]: 5.7—10.1% at
—4 years, although the predictors of mortality listed above
ere partially excluded in those studies. In addition, the
ncidence ratio of deﬁnite ST events (0.54%) at the present
ean follow-up periods were particularly lower than those
n previous reports after primary stenting using SES in more
han 150 STEMI patients [1—3]: 1.9—3.6% at 3—4 years,
lthough the predictors of ST listed above were partially
xcluded in those studies. This low incidence of deﬁnite
Ts was attributable to the acceptable low incident ratio
f post-discharge cardiac event in this clinical practice set-
ing. First of all, in the present cohort of 568 consecutive
apanese STEMI patients, none of the incidences of early
eﬁnite ST events was one of the major reasons for the lower
ncidence of total deﬁnite ST events after primary stenting,
ecause the incident ratio of early deﬁnite ST occurred in
.6—1.3% in other studies after SES treatment [1—3]. This
dvantage of the present cohort would be primarily due to
ptimal stenting techniques (technical factors) [31], such as
etter high-pressure dilation (close to the rated value in the
resent study) compared to previous reports (close to the
ominal value) [1]; high-pressure ballooning [15,16] to pre-
ent no-/slow-ﬂow phenomenon with an efﬁcient utilization
f distal protection using the PercuSurge GuardWire system
17], one of the predictors of ST [31]; and efﬁcient use of
VUS-guidance [32], particularly in the SES group (Table 1).
one of the late ST events in the present cohort might be
ue to this technical beneﬁt or due to the performing ratio
f fu CAG (more than 70%), because the late ST events were
onsidered to be related to the aggressive restenosis process
33]. The very low incidence of VLST (0.54%) in the present
apanese STEMI patients compared to those western reports
1—3] should be estimated in a larger scale cohort with
urther longer intervals, because many factors: persistent
nﬂammation (hypersensitivity), incomplete endothelializa-
o
m
t
[
iession analysis are shown. The deﬁnitions of the variables are
ion, late malapposition, and persistent contrast stains are
onsidered to relate to VLST [33].
The angiographic efﬁcacy of SES was primarily due to
signiﬁcant decrease in the mean value of late lumi-
al loss and the incidences of binary restenosis and TLR
approximately 60% reduction) after the fu CAG compared
o those of BMS (Table 4). This efﬁcacy of SES in pri-
ary stenting is consistent with previous prospective reports
1—4]. The high incidences of binary restenosis and TLR
ave been a limitation in using BMS for the treatment of
TEMI [4]. On the other hand, SES was a protective pre-
ictor of binary restenosis in STEMI (Table 5), although
he adverse baseline characteristics, as described above,
ere present in the SES group (Table 3). In addition,
ig. 2 shows the midterm efﬁcacy of SES in the treatment
f STEMI. Thus, the present study indicates the midterm
avorable safety and efﬁcacy of primary stenting using
ES in a routine clinical setting in patients with STEMI.
he study also determines the adverse baseline charac-
eristics of the SES group through a historical comparison
ith those in the BMS group. Thus, a large-scale, long-
erm, randomized controlled trial is needed to clarify the
urability of primary stenting using DES in Japanese STEMI
atients.
Several limitations must be taken into account. First,
he present study was a retrospective, non-randomized, and
ingle-center analysis. The SES use ratio after SES approval
96.4%) was very high. Thus, the outcomes of SES were
ompared with those of BMS through a historical compar-
son. Second, the duration of dual antiplatelet therapy was
ependent on the doctor’s judgment, particularly for the
ES group. The number of patients who discontinued the
edical therapy, including the dual antiplatelet therapy,
ue to surgical and bleeding complications, was not fully
xamined nor was low compliance. However, there was no
ncrease in the number of post-discharge events or deﬁ-
ite ST events (Table 1). Third, other consistent predictors
or cardiac events in STEMI patients, such as medicines,
enal dysfunction, and anemia, were not fully estimated.
ourth, since TLR was decided mainly by our visual estima-
ion, the occulo-stenotic reintervention after fu CAG was
ncluded, particularly in the SES group. The percentage
f TLR was similar to that of intermediate stenosis (%DS
ore than 45%) in the SES group (Table 4). This was due
o the beneﬁt of patency of the infarcted-related artery
21,34]. This issue involving the long-term outcome of re-
ntervention after primary stenting using DES or BMS along
[[
[
[
[
[
[
[
[
[Primary stenting using SES for STEMI in Japan
with cost-effectiveness [35] of the procedure should be fur-
ther investigated.
Conclusions
The midterm (mean interval, 3.5 years) clinical and angio-
graphic outcomes of primary stenting using SES in Japanese
STEMI patients in a clinical practice setting were favorable,
as determined by a historical comparison with those of BMS.
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